- Optimi (OPTI) has launched Blue Serenity, Canada’s first natural therapeutic psilocybin product
- Blue Serenity is standardized to contain a total of 25 milligrams of natural psilocybin in the form of EU-GMP biomass grown as Panaeolus cyanescens mushrooms cultivated at Optimi Labs Inc. in Princeton, British Columbia
- Blue Serenity will be available upon request to all legal psilocybin patients whose access has been approved by Health Canada
- Optimi Health Corp. (OPTI) is up 10.53 per cent, trading at C$0.42 per share at 9:20 am ET
Optimi (OPTI) has launched Blue Serenity, Canada’s first natural therapeutic psilocybin product.
Blue Serenity is standardized to contain a total of 25 milligrams of natural psilocybin in the form of EU-GMP biomass grown as Panaeolus cyanescens mushrooms cultivated at Optimi Labs Inc. in Princeton, British Columbia.
Blue Serenity was launched in collaboration with psilocybin patient advocate Thomas Hartle.
He said that the name “Blue Serenity” touches on the emotional and visual aspect of his psilocybin experience.
“Blue Serenity was born from an experience that took me from a state of extreme anxiety to a feeling of calm that I never knew existed.”
Optimi Health CEO Bill Ciprick called the launch of Blue Serenity a moment to pause and reflect on Hartle’s contributions to a world beyond psychedelics.
“Anyone who has entered the psychedelics space in the last two years will tell you that Thomas Hartle’s story of compassion and kindness inspired them in some way to want to make a difference,” said Ciprick. “We are tremendously excited to be partnering with Thomas to become the first Canadian company to launch a natural psilocybin product specifically to help patients seeking relief through the Special Access Program.”
He added that proceeds from the sale of Blue Serenity will directly benefit psilocybin patients through Hartle’s new charity, a venture that will provide access to psilocybin therapy for underserved adults.
Blue Serenity will be available upon request to all legal psilocybin patients whose access has been approved by Health Canada.
Optimi Health focuses on producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms for the health and wellness markets.
Optimi Health Corp. (OPTI) is up 10.53 per cent, trading at C$0.42 per share at 9:20 am ET.